Allogene Therapeutics CFO Geoffrey Parker sells $48,698 in stock

Geoffrey M. Parker, Chief Financial Officer of Allogene Therapeutics, Inc. (NASDAQ:ALLO), sold 36,342 shares of the company’s common stock on October 21, 2026. The shares were sold at a price of $1.34 each, totaling $48,698. This transaction was carried out to cover tax withholding obligations in connection with the vesting of restricted stock units and was not a discretionary trade by Mr. Parker. The sale comes as the stock trades near $1.25, down 46% over the past six months and close to its 52-week low of $1.04.

Following this transaction, Mr. Parker directly holds 1,045,877 shares of Allogene Therapeutics common stock. This updated beneficial ownership figure accounts for the forfeiture of 195,000 shares previously subject to performance restricted stock units granted on October 10, 2023. Additionally, the reported ownership includes 12,500 shares acquired on March 15, 2026, and 11,924 shares acquired on September 15, 2026, both through an employee stock purchase program. According to InvestingPro, the stock appears undervalued based on its Fair Value analysis. Investors can access detailed analysis through ALLO’s comprehensive Pro Research Report, available for this and 1,400+ other US equities.

In other recent news, Allogene Therapeutics reported its financial results for the second quarter of 2026, revealing a narrower-than-expected loss. The company posted adjusted earnings of negative $0.13 per share, surpassing analyst forecasts of a negative $0.17 per share. Revenue for the quarter was $4.64 million, significantly exceeding the forecast of $2,220, although the initial estimate was notably low. Additionally, Citizens reaffirmed its Market Outperform rating for Allogene, maintaining a price target of $6.00. This rating is based on an analysis of discounted earnings per share and revenue multiples, reflecting the company’s progress in clinical trials. The firm noted the advancements in Allogene’s CAR T pipeline as a key factor in its rating decision. These developments highlight the company’s ongoing efforts to innovate in the field of allogeneic CAR T therapies.